Merck & Co., Inc. Receives Complete Response Letter from the Food and Drug Administration for Use of Gardasil in Women Ages 27 through 45

Jan 9, 2009 - Merck & Co., Inc. announced today that the U.S. FDA has issued a second complete response letter regarding the supplemental biologics license application for the use of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] in women ages 27 though 45.

The details can be read here.